| Current Price | $0.59 | Mkt Cap | $3.5M |
|---|---|---|---|
| Open | $0.60 | P/E Ratio | -0.11 |
| Prev. Close | $0.59 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.56 - $0.60 | Volume | 70,117 |
| 52-Wk Range | $0.45 - $12.60 | Avg. Daily Vol. | 863,484 |
The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
| Current Price | $0.59 | Mkt Cap | $3.5M |
|---|---|---|---|
| Open | $0.60 | P/E Ratio | -0.11 |
| Prev. Close | $0.59 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $0.56 - $0.60 | Volume | 70,117 |
| 52-Wk Range | $0.45 - $12.60 | Avg. Daily Vol. | 863,484 |
Read the most recent pitches from players about BBI.
Recs
Jackgeary
(< 20)
Submitted: 10/28/2020 2:22:52 PM :
Start Price:
$3.94
NASDAQ:BBI Score:
-98.62
speculative biotech great tewchnology
Recs
SqwiiTrader
(< 20)
Submitted: 3/18/2014 7:03:47 PM :
Start Price:
$415.80
NASDAQ:BBI Score:
-214.66
prediction TOS
Recs
10qdetective
(< 20)
Submitted: 3/4/2014 1:45:46 AM :
Start Price:
$475.65
NASDAQ:BBI Score:
-227.55
Potential buyer in Merck?
Vical (VICL) is developing Allovectin, a first-in-class investigational DNA-based immunotherapeutic designed to stimulate both innate and adaptive immune responses in local tumors and distal metastases.
Of unique interest to Merck is that this immunotherapy is currently being evaluated in late-stage clinical trials as first-line treatment for Stage III and IV melanoma. Merck watchers might want to know, too, that Vical’s current CEO, Vijay Samant, previously spent 20 years with Merck in international sales and marketing.
Find the members with the highest scoring picks in BBI.
mjonesy1985 (96.49) Score: +551.87
The Score Leader is the player with the highest score across all their picks in BBI.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| rhinomaj | < 20 | 8/4/2009 |
|
3M | $1,190.70 | -99.95% | +327.56% | +427.51 | 0 Comment | |
| etaster | 30.40 | 12/3/2009 |
|
1Y | $919.80 | -99.94% | +283.67% | +383.61 | 0 Comment | |
| PIGMA | 24.43 | 6/2/2011 |
|
5Y | $1,168.65 | -99.95% | +223.66% | +323.61 | 0 Comment | |
| cIRCitmage | < 20 | 2/8/2011 |
|
NS | $639.45 | -99.91% | +223.34% | +323.25 | 0 Comment | |
| elayton | < 20 | 4/24/2008 |
|
3W | $1,143.45 | -99.95% | +223.18% | +323.13 | 0 Comment | |
| FUZZYMINKINS | < 20 | 7/11/2011 |
|
5Y | $1,351.35 | -99.96% | +221.73% | +321.69 | 0 Comment | |
| gogogoo | 70.32 | 1/30/2007 |
|
3Y | $1,993.95 | -99.97% | +217.59% | +317.56 | 0 Comment | |
| dwn88ir | 42.94 | 4/23/2012 |
|
5Y | $891.67 | -99.93% | +212.80% | +312.74 | 0 Comment | |
| petricko | 89.73 | 7/17/2007 |
|
3W | $1,622.25 | -99.96% | +189.85% | +289.81 | 0 Comment | |
| rknapton | 31.00 | 8/27/2013 |
|
5Y | $425.25 | -99.86% | +159.86% | +259.72 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
